Comparison
CJC-1295 vs Curcumin
Side-by-side of CJC-1295 and Curcumin. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.
CJC-1295
CJC-1295 peptide profile: GHRH analog forms (with-DAC ~7-day half-life, no-DAC Mod GRF 1-29 ~30 min), ipamorelin pairing, recovery use, dosing, side effects.
Curcumin
Curcumin supplement guide: turmeric extract at 500-1000 mg/day, piperine and Meriva for absorption, evidence in joint inflammation and mood.
Effects at a glance
CJC-1295
- •GHRH analog that binds the GHRH receptor on pituitary somatotrophs to release endogenous GH
- •DAC variant has ~7 day half-life via albumin binding; non-DAC variant ~30 minutes
- •Teichman 2006 trial showed sustained 2 to 10 fold IGF-1 elevation at 60 to 250 mcg/kg DAC dosing
- •Anecdotal protocols pair non-DAC CJC-1295 with Ipamorelin to mimic pulsatile GH release
- •Side effects: water retention, numbness or tingling at injection site, vivid dreams, transient flushing
- •No completed phase III RCTs; research-use-only and not FDA approved
Curcumin
- •Reduces osteoarthritis knee pain comparable to ibuprofen at 1500 mg/day enhanced formulation
- •Modest antidepressant effect (SMD ~0.34) as monotherapy or SSRI adjunct in major depression
- •Standard curcumin has ~3% bioavailability; Meriva, BCM-95, Theracurmin shift absorption 5-30 fold
- •Inhibits NF-kB and COX-2; reduces hs-CRP, IL-6, TNF-alpha in chronic inflammation
- •Antiplatelet effect at higher doses; meaningful interaction with warfarin and DOACs
- •Iron chelation can contribute to deficiency in already-marginal patients
Side-by-side
| Attribute | CJC-1295 | Curcumin |
|---|---|---|
| Category | peptide | natural |
| Also known as | CJC-1295 DAC, CJC-1295 no-DAC, Mod GRF 1-29, tesamorelin analog | turmeric extract, diferuloylmethane |
| Half-life (hr) ↗ | 168 | 7 |
| Typical dose (mg) ↗ | 0.1 | 500 |
| Dosing frequency | weekly (DAC); 1-3x daily (non-DAC) | 1 to 2 times daily with meals |
| Routes | subcutaneous | oral |
| Onset (hr) | 1 | 2 |
| Peak (hr) | 3 | 4 |
| Molecular weight | 3367.83 | 368.38 |
| Molecular formula | C152H252N44O42 | C21H20O6 |
| Mechanism | Binds the GHRH receptor on pituitary somatotrophs, stimulating pulsatile growth-hormone release. The DAC modification extends plasma residence by tethering the peptide to serum albumin via a maleimide-cysteine bond. | Inhibits NF-kB transcription factor, COX-2, and lipoxygenase; activates AMPK and Nrf2; modulates JAK-STAT and PI3K-Akt kinase signaling. Pleiotropic anti-inflammatory and antioxidant effects. |
| Legal status | Not FDA approved; research-use-only grey market; banned by WADA | Dietary supplement (global) |
| WADA status | banned | allowed |
| DEA / Rx | Not FDA approved; not scheduled; research-chemical status | Not scheduled |
| Pregnancy | Insufficient data; not recommended | Culinary turmeric is safe; supplemental curcumin best avoided in pregnancy |
| CAS | 446262-90-4 | 458-37-7 |
| PubChem CID | 91971820 | 969516 |
| Wikidata | Q5012154 | Q312266 |
Safety profile
CJC-1295
Common side effects
- injection-site reactions
- water retention
- numbness or tingling at injection site
- vivid dreams
- transient flushing
- head pressure or mild headache
Contraindications
- pregnancy
- active malignancy
- diabetic retinopathy (theoretical)
- history of pituitary tumor
Interactions
- Ipamorelin: synergistic GH release; commonly co-administered in anecdotal protocols(minor)
- insulin: GH-induced insulin resistance can shift glycemic control over weeks(moderate)
- corticosteroids: blunt GH-axis response; reduce expected efficacy(moderate)
Curcumin
Common side effects
- nausea
- diarrhea
- dyspepsia
- yellow stool (benign)
Contraindications
- active gallstones (curcumin stimulates gallbladder contraction)
- severe biliary obstruction
- scheduled elective surgery (discontinue 1-2 weeks prior)
Interactions
- warfarin and DOACs: additive antiplatelet and anticoagulant effects; meaningful bleeding risk at 1000+ mg/day(major)
- aspirin and NSAIDs: additive antiplatelet effect(moderate)
- tacrolimus and cyclosporine: CYP3A4 and P-gp modulation may alter drug levels(moderate)
- iron supplements: curcumin chelates iron; can contribute to deficiency in marginal patients(moderate)
- chemotherapy agents: potential interference with multiple agents; coordinate with oncology team(major)
Which Should You Take?
Curcumin comes out ahead for most readers on the criteria we weight: 3 catalogued goals, OTC dietary supplement, oral dosing, with a Tier-B outcome catalogued. CJC-1295 is the right call when one of the conditionals below applies.
- → If your priority is growth-hormone axis, pick CJC-1295.
- → If your priority is body composition, pick CJC-1295.
- → If your priority is healthspan extension, pick Curcumin.
- → If your priority is joint health, pick Curcumin.
Edge case: If you want to avoid research-only / gray-market sourcing, Curcumin is the more accessible choice.
Default choice: Curcumin. Lower friction to source, and broader goal coverage. Reach for CJC-1295 only if your priority sits squarely in the goals it owns above.
This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.
Common questions
What is the difference between CJC-1295 and Curcumin?
CJC-1295 and Curcumin differ in category (peptide vs natural), mechanism, and typical dosing. See the side-by-side table for full details.
Which has a longer half-life, CJC-1295 or Curcumin?
CJC-1295 half-life is 168 hours; Curcumin half-life is 7 hours.
Can you stack CJC-1295 with Curcumin?
Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.
Go deeper